Research Collaboration and License Agreements - Additional Information (Details)	1 Months Ended	3 Months Ended		12 Months Ended
	Nov. 30, 2017 USD ($) Target	Mar. 31, 2021 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Jul. 31, 2019 USD ($)
Research Collaboration And License Agreements [Line Items]
Revenue recognized on research collaboration and license agreements		$ 5,500,000
Changes in deferred revenue due to additions to deferred revenue		(2,537,715)	$ (2,211,793)
Unsatisfied performance obligations expected to be recognized as revenue		42,500,000
Bayer Collaboration Agreement
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised								$ 17,500,000
Changes in deferred revenue due to additions to deferred revenue		3,000,000.0
Bayer Collaboration Agreement | Research Funding Payments
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised		3,000,000.0	$ 3,000,000.0					$ 1,500,000
Bayer Collaboration Agreement | Research Funding Payments | Scenario Forecast
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised					$ 10,500,000
Bayer Collaboration Agreement | Stock Purchase Agreement
Research Collaboration And License Agreements [Line Items]
Fair value of the shares sold		2,900,000
Additional consideration received		2,900,000
Pfizer, Inc.
Research Collaboration And License Agreements [Line Items]
Upfront non-refundable payment and certain additional payments received				$ 28,000,000.0
Pfizer, Inc. | Option Exercised
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised		$ 4,900,000
Pfizer, Inc. | Substitution Target Payments
Research Collaboration And License Agreements [Line Items]
Contract revenue receivable if milestones achieved or options for all targets exercised						$ 3,000,000.0	$ 1,200,000
Genentech, Inc. and F. Hoffman-La Roche Ltd.
Research Collaboration And License Agreements [Line Items]
Upfront non-refundable payment and certain additional payments received	$ 34,500,000
Additional upfront non-refundable amount received under previous agreement	$ 11,000,000.0
Number of designated targets | Target	10